EGFR and non-small cell lung carcinoma: Targeted therapies with EGFR-TKIs, such as gefitinib, erlotinib, and afatinib, have been well-established to effectively treat EGFR mutant NSCLC [22]; however, not all EGFR mutations are sensitive to EGFR-TKI treatment.